Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies - Marketscreener.com

1 year ago 56

Homepage Equities China Shanghai Stock Exchange Heilongjiang ZBD Pharmaceutical Co., Ltd. News Summary     603567   CNE100002219 (603567) Add to my list   Report End-of-day punctuation Shanghai Stock Exchange  -  2022-12-04 16.11 CNY   +8.27% 02:37a Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology connected Medicine Supplies MT 11/04 Heilongjiang ZBD Gets Approval for Traditional Medicine Product MT 11/02 Heilongjiang ZBD's Anti-Pulmonary Fibrosis Drug Gets U.S. Patent MT Summary Quotes Charts News Ratings Calendar Company Financials Funds   Summary Most relevant All News Other languages Press Releases Official Publications Sector news 12/06/2022 | 02:37am EST MT Newswires 2022 Stocks mentioned successful the article Change Last 1st jan. HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD.  8.27% 16.11 5.29% KANGYUE TECHNOLOGY CO., LTD.  0.29% 10.29 -32.30% UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH)  0.22% 6.9846 10.16% All quality about HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD. 02:37a Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology connected Medicine Supplies MT 11/04 Heilongjiang ZBD Gets Approval for Traditional Medicine Product MT 11/02 Heilongjiang ZBD's Anti-Pulmonary Fibrosis Drug Gets U.S. Patent MT 10/27 Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months .. CI 10/11 Tranche Update connected Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan annou.. CI 08/25 Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year En.. CI 08/03 Tranche Update connected Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan annou.. CI 06/10 Huzhou Saihan Equity Investment Partnership Enterprise (Limited Partnership) completed .. CI 06/10 Heilongjiang ZBD Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 millio.. CI 06/09 Heilongjiang ZBD Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI More news Financials Sales 2021 4 127 M 593 M 593 M Net income 2021 332 M 47,7 M 47,7 M Net Debt 2021 1 380 M 198 M 198 M P/E ratio 2021 39,8x Yield 2021 0,69% Capitalization 15 147 M 2 176 M 2 176 M EV / Sales 2020 3,27x EV / Sales 2021 3,83x Nbr of Employees 3 245 Free-Float 19,2% More Financials Chart HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD. Duration : Period : Full-screen chart Technical investigation trends HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD. Short Term Mid-Term Long Term Trends Bullish Bullish Bullish Technical analysis Income Statement Evolution More Financials Managers and Directors Tong Hua Fang Chairman & General Manager Xiu Ping Ge Chief Financial Officer Pei Bao Lan Chairman-Supervisory Board Shao Hua Cui Independent Director Ya Fei Wang Director More astir the company Sector and Competitors 1st jan. Capi. (M$) HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD. 5.29% 2 176 JOHNSON & JOHNSON 4.57% 467 679 ELI LILLY AND COMPANY 35.67% 356 089 ABBVIE INC. 21.08% 289 331 NOVO NORDISK A/S 22.04% 285 887 PFIZER, INC. -13.78% 285 774 More Results

1. Homepage
2. Health
3. Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies - Marketscreener.com